Newsletters The altcoin behind an $11B privacy play The Cheap InvestorAugust 31, 20260 August 31, 2026 Bonus Content: The Consumer Markdown: Cheap or Broken? A note from our friends at Crypto 101(ad) Dear…
Economy The Regulation Nobody Talks About Is Building the Edge The Cheap InvestorAugust 31, 20260 Data-sovereignty laws are pushing some workloads out of the cloud and into local hardware. That is a real edge computing tailwind.
Newsletters China’s Stimulus Won’t Fix a Slowing Economy The Cheap InvestorAugust 31, 20260 August 31, 2026 Beijing’s interest-subsidy expansion and 2 trillion yuan bond push Hey there, bargain hunter. Beijing unveiled its latest…
Newsletters Wall Street Has a Blunt New Name for What’s Happening to the Dollar The Cheap InvestorAugust 31, 20260 August 31, 2026 Bonus Content: The Regulation Nobody Talks About Is Building the Edge Sponsored Wall Street Has a Blunt…
TCI Exclusives Whose Gross Margin Pays for Cheap Tokens? The Cheap InvestorAugust 31, 20260 Google’s price attack on Anthropic and Microsoft shows who can cut and who bleeds.
Newsletters Monday Mornings Just Got Interesting The Cheap InvestorAugust 30, 20260 August 30, 2026 Bonus Content: At 10x Earnings, Is LULU Cheap or Broken? Sponsored You won’t believe what I’ve been…
TCI Exclusives Frontline’s $2.61 Dividend Is Earning Its Keep. The Question Is What Happens Next. The Cheap InvestorAugust 30, 20260 With a key VLCC route near WS570 and one-year charters locked at $120,000, the real debate is how Hormuz diplomacy reshapes the payout.
Newsletters Bill Gates’ AI power prize The Cheap InvestorAugust 30, 20260 August 30, 2026 Bonus Content: HP at $29.62: Value Trap or Cheap Cash Machine? Sponsored Editor’s Note: When the 2008…
Business How Allocators Are Pricing the AI Buildout The Cheap InvestorAugust 30, 20260 Phase 2 of the chip tariff could turn server OEM bills of materials into a trade-policy variable, and the data center carve-out is the only number that matters.
Economy MRNA Tripled. Now It Has a $2.6B Offering. The Cheap InvestorAugust 29, 20260 Moderna’s Phase 3 melanoma win was historic. Days later, a convertible note deal is the real question investors must answer.